There is growing interest in alternate "business models" of R&D as potential solutions to some of the shortcomings of the current R&D system -- namely, high prices, unmet innovation needs in certain areas, and limited availability. There has been significant experimentation in alternate business models for neglected diseases (ND) with the creation of over 20 Product Development Partnerships (PDPs) and about two decades of experience now available. PDPs have demonstrated the feasibility of developing new medicines through non-commercial approaches, but understanding has been limited of how they compare to commercial R&D. Marcela Vieira will present a recently published study analysing data on the costs and efficiency of PDPs compared to estimates from commercial R&D, and exploring similarities and differences between the two business models.

Speakers

• Marcela Vieira, Researcher and Project Coordinator of the Knowledge Network for Innovation and Access to Medicines, Global Health Centre
• Moderator: Suerie Moon, Co-Director, Global Health Centre
   

Event Materials

• Research Paper: Marcela Vieira, Ryan Kimmitt and Suerie Moon (2021) Non-Commercial Pharmaceutical R&D: What Do Neglected Diseases Suggest about Costs and Efficiency?
• Working Paper: Suerie Moon, Marcela Vieira and Ryan Kimmitt (2020) Do costs, timeframes and attrition rates differ between non-commercial and commercial biomedical R&D? A study of neglected diseases R&D and the P2I model
• Presentation by Marcela Vieira
• Q&A Session with the Participants